Articles On Orthocell (ASX:OCC)

The S&P/ASX 200 Index (ASX: XJO) is having another positive session on Wednesday. At the time of writing, the benchmark index is up 0.2% to 8,086.6 points. Four ASX shares that are rising more than most today are listed below. Here's...

Orthocell has added Canada to its string of regulatory approvals for its flagship nerve repair product.

Highlights: ASX200 closed higher, led by strength in ASX Energy Stocks, IT, and Consumer Discretionary sectors Ainsworth Game Technology rose significantly after announcement of takeover by an Austrian firm Brambles and Lion...

ASX uranium stocks have soared after the US administration flagged U3O8 would be included in tariff exemption list Energy sector up more than 2pc, with Small Ords index close behind Utilities, Info Tech, Resources, Real Estate sectors all...

Highlights: Energy stocks led the ASX200 higher, while Materials lagged. Ainsworth Game Technology shares climbed following an acquisition announcement. Orthocell and Lynas Rare Earths posted gains on positive business updat...

Woodside Energy Group Ltd (ASX: WDS) shares are in the spotlight on Tuesday. That's because the energy giant has announced a major new investment decision that could reshape its future. At the time of writing, the company's shares are up 1%...

Orthocell gains regulatory approval for flagship nerve repair Remplir in lucrative Thai market Approval granted sooner than expected, unlocking door to growing $84 million Thai nerve repair market This tops off good month for Orthocell, wh...

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week in a positive fashion. The benchmark index rose 0.35% to 7,997.1 points. Will the market be able to build on this on Tuesday? Here are five things to watch: ASX 200 expected...

Key Highlights The ASX200 saw a moderate increase, driven by strength in Energy, IT, and Discretionary sectors. Ainsworth Game Technology experienced a significant rise after acquisition news. Brambles and Liontown Resources...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a positive start to the week's trading this Monday, despite an afternoon dip from the initial highs we saw this morning. By the time the markets closed, the...

The ASX200 closed up 0.36% at 7,997 points. The Energy sector lead the market higher, up 1.6%, followed by IT, up 1.4%, and Discretionary, up 1.3%. Materials was the only sector in the red, down 0.6%. In the Green Ainsworth Game...

WA biotech Orthocell has received the green light to start selling its nerve repair product into the Thai market, worth $131 million.

The S&P/ASX 200 Index (ASX: XJO) is starting the week on a positive note. At the time of writing, the benchmark index is up 0.7% to 8,023.9 points. Four ASX shares that have failed to follow the market higher today are listed below. He...

The S&P/ASX 200 Index (ASX: XJO) is having a strong session on Monday. At the time of writing, the benchmark index is up 0.8% to 8,033.6 points. Four ASX shares that are rising more than most today are listed below. Here's why they are...

Telix Pharmaceuticals Ltd (ASX: TLX) shares are tumbling on Monday morning. At the time of writing, the radiopharmaceuticals company's shares are down 8% to $26.35. Why are Telix shares sinking? Investors have been selling the company's sha...

Lynas Rare Earths Ltd (ASX: LYC) shares are catching the eye on Monday. At the time of writing, the rare earths producer's shares are up 3% to $8.56. Why are Lynas shares racing higher? Investors have been bidding Lynas shares higher today...

Every now and again, an ASX company emerges that captures the hearts and minds of investors.  It doesn't happen every year, but it certainly happens more often than you think.  From Droneshield (ASX: DRO) to ProMedicus (ASX: PME) to S...

Paladin Energy Ltd (ASX: PDN) shares have been on fire these past two days. On Wednesday, shares in the S&P/ASX 200 Index (ASX: XJO) uranium stock rocketed an eye-watering 24.6% following the release of the company's quarterly update....

On Wednesday, the S&P/ASX 200 Index (ASX: XJO) was on form and stormed higher. The benchmark index rose 1.3% to 7,920.5 points. Will the market be able to build on this on Thursday? Here are five things to watch: ASX 200 expected to r...

The US Food and Drug Administration might be in a mess, but a slew of ASX biotechs can’t complain that the agency’s approval process has stalled. This month, the FDA approved Artrya’s (ASX:AYA) arterial plaque detection tool, Salix Coronary...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a hump day boost this Wednesday, rocketing higher following a surge of optimism out of the United States. By the time trading wrapped up today, the ASX 200...

Regenerative medicine developer Orthocell (ASX:OCC) has appointed the first four US distributors for its flagship nerve repair product Remplir. The appointments follow FDA clearance for Remplir which landed earlier this month, and Orthocell...

Regenerative medicine company Orthocell (ASX: OCC) has appointed the first four US distributors for the company’s flagship nerve repair product Remplir. The move follows regulatory clearance from the US Food and Drug Administration earlier...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1.6% to 7,942.8 points. Four ASX shares that are rising more than most today are listed below....

S&P/ASX 200 Index (ASX: XJO) financial stock Insignia Financial Ltd (ASX: IFL) is charging higher today. Insignia shares closed yesterday trading for $3.56. In late morning trade on Wednesday, shares are changing hands for $3.67 apiece...

It has been another good day for owners of Orthocell Ltd (ASX: OCC) shares. In morning trade, the ASX All Ords stock is up 10% to $1.29. This means that the regenerative medicine company's shares are now up 240% over the past 12 months. Why...

Orthocell (ASX:OCC) has locked in a U.S. distributor deal for its flagship product and biotech punter favourite Remplir, leaving the company confident U.S. sales are about to kick off. Listen to the HotCopper podcast for in-depth discus...

Woodside Energy Group Ltd (ASX: WDS) shares are having a strong session on Wednesday. In morning trade, the energy giant's shares are up almost 4% to $20.47. This follows the release of the company's first quarter update before the market o...

I'm always on the lookout for exciting ASX dividend shares that offer investors a steady flow of dividends. With everything going on in the economic world, particularly with tariffs by the US, Aussies may want to find businesses that can...

Good Afternoon and welcome to HotCopper’s Market Close for Thursday 17 April, I’m Jonathon Davidson. The ASX went its own way despite Wall Street’s overnight finish to close out this shortened trading week, climbing back above the 7,800...

When you think of S&P/ASX 200 Index (ASX: XJO) dividend stocks, A2 Milk Co Ltd (ASX: A2M) may not be the first company that comes to mind. But that could be set to change. On the back of strong half-year results, the dairy company decl...

WA regenerative medicine company Orthocell has posted a near-40 per cent jump in fourth quarter revenue just days after it won a major regulatory clearance in the US.

Highlights: Orthocell lodges application for Hong Kong approval, expanding its global biotech footprint Digico REIT experiences a notable rise despite limited direct announcements Mineral Resources benefits from iron ore rec...

Good Afternoon and welcome to HotCopper’s Market Close for Thursday 10th of April, I’m Jonathon Davidson. It was a happier day for traders with a tariff reprieve from Trump who was compelled to do so by because nobody was buying US bonds...

Orthocell receives regulatory approval in Brazil for dental guided bone regeneration product Striate+ Company working with global distribution partner BioHorizons on initial market launch in Brazil in Q4 Orthocell has applied for regulator...

Orthocell has been approved to start selling its dental bone repair product Striate+ into the $US65 million ($109m) Brazilian market. 

Orthocell says FDA approval for its Remplir nerve regeneration conduit was timely in more ways than one The approval leverages the $80 million Orthocell spent to develop its collagen-based Celgro platform Inspired by its Australian experie...

Tylah Tully chats with Orthocell’s (ASX:OCC) managing director and CEO Paul Anderson to talk through the company’s major milestone, after 10 year its received FDA approval for its nerve repair product Remplir. But its plans for global expan...

 Truscreen and Mesoblast say: we won’t be ‘tariffed’ Orthocell girds for US Remplir rollout Pacific Edge sales slump amid reimbursement uncertainties   Post Liberation Day, announcements are flowing from US-exposed life sciences companie...

The ASX dividend stock Sonic Healthcare Ltd (ASX: SHL) has dropped 43% since the COVID-19 peak of December 2021. This business provides pathology services for patients in a number of countries, including Australia, the UK, Germany, Switzerl...

Last Friday, it was announced that ASX All Ords company Orthocell Ltd (ASX: OCC) had received approval from the Food and Drug Administration (FDA) to sell its nerve product Remplir in the United States. For investors, this news had been...

Since US President Donald Trump unveiled his tariffs last week, very few ASX companies have escaped the broad based market sell off. Based on share price reactions alone, it isn't obvious which companies are directly impacted by Trump's tar...

ASX heath sector falls 2.1%, while broader markets also fall 3.8% for the same period as US tariffs spook global markets Regenerative medicine company Orthocell receives US FDA approval for peripheral nerve repair product Remplir  HealthIn...

It was a calamitous end to a calamitous week for the S&P/ASX 200 Index (ASX: XJO) this Friday. The ongoing fallout from President Donald Trump's new tariffs once again smashed the ASX 200 today. T...

The S&P/ASX 200 Index (ASX: XJO) plummeted by 191.9 points or 2.44% on Friday to finish the week at 7,667.8 points. Uncertainty about how the newly announced reciprocal US tariffs will impact ASX 200 shares fuelled today's dive....

ASX drops heavily as Trump’s tariffs spark chaos Energy stocks hit hard Breville and Ansell scramble to neutralise tariffs   The ASX copped another big drop on Friday, tumbling 2.44% as global markets went into freefall. For the week, the...

It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these...

Headlines The ASX healthcare sector has seen notable activity with updates from Mesoblast Limited and Orthocell Limited. U.S. trade policies continue to impact various industries, including mining and energy companies listed on the ASX...

The ASX has been down 1.5% at 7,739 points this morning. There’s been carnage on the ASX and the Energy sector has been enduring a bloodbath, followed by IT and Utilities. Staples and Health Care are the only sectors in positive terri...

The S&P/ASX 200 Index (ASX: XJO) is having a tough finish to the week. In afternoon trade, the benchmark index is down 1.45% to 7,743.4 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they...